Pirotinib

Drug Profile

Pirotinib

Alternative Names: KBP-5209

Latest Information Update: 08 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sihuan Pharmaceutical Holdings Group; XuanZhu Pharma
  • Class
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 02 Jun 2017 Adverse events and efficacy data from a first-in-human phase I trial presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 29 Mar 2016 Phase-I clinical trials in Solid tumours in China before March 2016 (PO)
  • 20 Mar 2015 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (PO) (MDACC-2014-0891)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top